Literature DB >> 24838519

Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013.

Marcus J Drake1.   

Abstract

AIM AND METHODS: Overactive bladder syndrome (OAB) has a symptom-based definition. Following a presentation of issues, the definition was subjected to expert discussion at the International Consultation on Incontinence Research Society to identify key issues.
RESULTS: OAB is a widely used term; it is a pragmatic approach to categorizing a recognized group of patients, and is understood by the patients, however, expert opinion suggested several issues for which additional evidence should be sought. Naming an organ (bladder) in the condition may suggest underlying mechanism, when contributory aspects may lie outside the bladder. No severity thresholds are set, which can cause uncertainty. Urgency is prominent in the definition, but may not be prominent in patients whose adaptive behavior reduces their propensity to urgency. OAB can co-exist with other common conditions, such as benign prostate enlargement (BPE), stress incontinence or nocturnal polyuria. Consensus led by the International Continence Society can be attempted for aspects such as "fear of leakage." To develop a new definition, more substantive evidence is needed for key elements, and until such evidence is available, full redefinition is not appropriate. Thus, the medical profession should accept constructive compromise and work supportively.
CONCLUSIONS: The ICI-RS proposes that the terminology is slightly rephrased as: "overactive bladder syndrome (OAB) is characterized by urinary urgency, with or without urgency urinary incontinence, usually with increased daytime frequency and nocturia, if there is no proven infection or other obvious pathology." More substantive changes would require additional scientific evidence. Strengths, limitations, and practicalities of the definition of OAB were discussed at the ICIRS meeting 2013. Following a presentation of issues, the definition was subjected to expert discussion.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  frequency; increased daytime frequency; nocturia; overactive bladder; urgency; urgency urinary incontinence

Mesh:

Year:  2014        PMID: 24838519     DOI: 10.1002/nau.22609

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  37 in total

1.  OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.

Authors:  Nick Freemantle; Kristin Khalaf; Clara Loveman; Sanja Stanisic; Dmitry Gultyaev; Johanna Lister; Marcus Drake
Journal:  Eur J Health Econ       Date:  2015-10-19

2.  Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.

Authors:  Honglin Ding; Ning Li; Xiaoning He; Bing Liu; Liming Dong; Yili Liu
Journal:  Int Urol Nephrol       Date:  2017-07-29       Impact factor: 2.370

Review 3.  Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases.

Authors:  Paul S J Miller; Harry Hill; Fredrik L Andersson
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

4.  Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT.

Authors:  Amanda L Lewis; Grace J Young; Lucy E Selman; Caoimhe Rice; Clare Clement; Cynthia A Ochieng; Paul Abrams; Peter S Blair; Christopher Chapple; Cathryn Ma Glazener; Jeremy Horwood; John S McGrath; Sian Noble; Gordon T Taylor; J Athene Lane; Marcus J Drake
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

Review 5.  Clinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome.

Authors:  Monika Vij; Marcus J Drake
Journal:  Ther Adv Urol       Date:  2015-10

6.  Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.

Authors:  Andrea Tubaro; José E Batista; Victor W Nitti; Sender Herschorn; Christopher R Chapple; Mary Beth Blauwet; Emad Siddiqui; Moses Huang; Matthias Oelke
Journal:  Ther Adv Urol       Date:  2017-05-10

7.  Terminology for bladder health research in women and girls: Prevention of Lower Urinary Tract Symptoms transdisciplinary consortium definitions.

Authors:  Jerry L Lowder; Tamara G Bavendam; Amanda Berry; Sonya S Brady; Colleen M Fitzgerald; Cynthia S Fok; Patricia S Goode; Cora E Lewis; Elizabeth R Mueller; Diane K Newman; Mary H Palmer; Leslie Rickey; Ann Stapleton; Emily S Lukacz
Journal:  Neurourol Urodyn       Date:  2019-04-08       Impact factor: 2.696

Review 8.  The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Authors:  Karl-Erik Andersson; Nurul Choudhury; Jean-Nicolas Cornu; Moses Huang; Cees Korstanje; Emad Siddiqui; Philip Van Kerrebroeck
Journal:  Ther Adv Urol       Date:  2018-07-06

9.  Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).

Authors:  P Abrams; C Kelleher; D Staskin; R Kay; A Martan; I Mincik; D Newgreen; A Ridder; A Paireddy; R van Maanen
Journal:  World J Urol       Date:  2016-08-11       Impact factor: 4.226

Review 10.  The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis.

Authors:  Sofia Tsiapakidou; Apostolos Apostolidis; Konstantinos Pantazis; Grigoris F Grimbizis; Themistoklis Mikos
Journal:  Int Urogynecol J       Date:  2021-08-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.